Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus ...
Journal Information
Vol. 155. Issue 9.
Pages 409-410 (November 2020)
Vol. 155. Issue 9.
Pages 409-410 (November 2020)
Scientific letter
DOI: 10.1016/j.medcle.2020.05.023
Full text access
Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease
Incidencia de trombocitopenia inducida por heparina en pacientes con enfermedad por coronavirus 2019
Visits
...
Roberto Lozanoa,
Corresponding author
rlozano@salud.aragon.es

Corresponding author.
, María-Esther Francob
a Hospital Real de Nuestra Señora de Gracia, Servicio de Farmacia, Zaragoza, Spain
b Hospital Real de Nuestra Señora de Gracia, Servicio de Hematología, Zaragoza, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Value of the biochemical and hematological variables studied, baseline and at 5-10 corresponding to the 3 cases of patients with suspected heparin-induced thrombocytopaenia.
Full Text
To the Editor:

Among patients with coronavirus disease 2019 (COVID-19), thrombogenicity is a common abnormality. Due to this, the prophylactic application of low molecular weight heparin (LMWH) has been recommended by several expert consensus,1 as one of its most serious complications is the well-known heparin-induced thrombocytopaenia (HIT).2

Additionally, as recent publications have reported the presence of spontaneous HIT in critical patients affected by COVID-19 and naive for heparin,3 and that therefore a higher percentage and/or intensity than expected could lead to the presentation of said disorder, the objective of this study has been to quantify said incidence of HIT among patients affected by moderate or severe COVID-19.

For this, we have retrospectively analysed a cohort of COVID-19 patients (diagnosed by the polymerase chain reaction test or PCR), under prophylactic treatment with LMWH (bemiparin 2,500−3,500 IU Anti-Xa). They were consecutively admitted to the Hospital Real de Nuestra Señora de Gracia, internal medicine department, between 1 st February and 16th March 2020, with a platelet count every 3−5 days and baseline between 100 and 500 × 103/ mm3.

The final study sample was 43 patients: 51% male, age 73.5 (± 16.9), body mass index 27.4 (±4.7), procalcitonin 0.4 (±1.5) ng/mL, leukocytes 8.3 (±4.5) 103/mm3, glomerular filtration (CDK-EPI) 70.2 (±21.3) mL/min, prothrombin time 12.7 (±1.2) s, Clauss fibrinogen 611 (±151), ferritin 814 (±495) ng/mL and D-dimer 3995 (±7092) ng/mL; of which 42% were being treated with hydroxychloroquine and 35% with hydroxychloroquine and lopinavir + ritonavir; 17 had associated risk factors: 35% DM2, 64.7% arterial hypertension and 17.6% renal failure.

The results identified 3 patients (6.9% of the sample), all male and aged 45, 71 and 90 years, whose risk quantification of iatrogenic thrombocytopaenia obtained a value of 6, according to the 4 Ts scoring system.2 This meant they had a high probability of presenting HIT (Table 1). The incidence of HIT observed in our cohort (6.9%), although of moderate intensity (minimum platelet count reached > 100), seems to suggest, as described by Xuan et al.,3 that prior exposure to heparin is not absolutely necessary to induce HIT in COVID-19 patients, and that HIT can occur spontaneously as a result of SARS-CoV-2 infection.

Table 1.

Value of the biochemical and hematological variables studied, baseline and at 5-10 corresponding to the 3 cases of patients with suspected heparin-induced thrombocytopaenia.

  Case 1Case 2Case 3
Variable  Baseline  5−10 d  Baseline  5−10 d  Baseline  5−10 d 
Procalcitonin. ng/mL.  1.0  0.9  0.198  0.065  0.136  1.81 
Leukocytes 103/mm3  12.2  16.9  22  7.4  3.7  3.3 
Glomerular filtration (CDK-EPI). mL/min  42  31  80  85  90  90 
Prothrombin time. s  13.9  15.4  14.9  12.8  12.8  11.7 
Clauss fibrinogen  559  434  152  128  613  450 
Ferritin. ng/mL  211  136  1.339  1.014  839  1.088 
D-dimer ng/mL  448  676  4.234  4.125  1.287  790 
Platelets 103/mm3  239  111  182  90  385  186 
Platelet decrease ≥ 50%  YesYesYes
Thrombosis  NoNoNo
Other causes thrombocytopenia  NoNoNo
4Ts score  666

Values are presented as mean (standard deviation).

d: days.

Our results show a high occurrence of HIT (6.9%) among COVID-19 patients under prophylactic treatment with LMWH. However, the platelet decline was moderate and transitory, with recovery occurring during convalescence, either because the viral infection was less severe or because lower heparin doses were used. Therefore, although several authors have reported a protective effect of anticoagulation with heparin in severe COVID-19 patients,4 the potential risk of HIT should be highlighted, especially when using high doses.

Regarding the limitations of this study, it should be noted that it is a retrospective design, and it focuses solely on the exploration of thrombocytopaenia. The influence of other therapies (for example, hydroxychloroquine) has not been evaluated and additionally, it is possible that there has been a ‘non-pharmacological change’ in the patients’ treatment, during the study period, in accordance with advancing knowledge of the COVID-19 pathophysiology. However, due to the lack of specific drugs against this infection, most of the patients received a similar treatment and, therefore, we believe that the results of the current study still have some clinical importance.

In conclusion, the incidence of HIT observed in patients with COVID-19, undergoing thromboprophylactic treatment with LMWH, is high (6.9%) although of moderate intensity. Therefore, in patients with a strong suspicion of HIT, heparin treatment should be suspended and/or continued with an alternative anticoagulant treatment, to avoid the high risk of HIT-induced thrombosis.

References
[1]
J.-F. Llitjos, M. Leclerc, C. Chochois, J.M. Monsallier, M. Ramakers, M. Auvray.
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.
J Thromb Haemost., (2020),
[2]
T.E. Warkentin, A. Greinacher.
Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest, 126 (2004), pp. 311-337
[3]
Xuan L, Xiaopeng Z, Yongjiu X, Ting G, Guangfei W, Zhongyi W, et-al. Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. medRxiv. 10.1101/2020.04.23.20076851.
[4]
N. Tang, H. Bai, X. Chen, J. Gong, D. Li, Z. Sun.
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.
Military Medical Research, 7 (2020), pp. 19

Please cite this article as: Lozano R, Franco ME. Incidencia de trombocitopenia inducida por heparina en pacientes con enfermedad por coronavirus 2019. Med Clin (Barc). 2020;155:409–410.

Copyright © 2020. Elsevier España, S.L.U.. All rights reserved
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.